-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Diabetes is a group of metabolic diseases characterized by hyperglycem.
According to the pathogenesis, diabetes can be divided into type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus and special type of diabetes mellit.
China is a big country with diabet.
According to relevant data, the number of diabetic patients in China will exceed 140 million in 202It is estimated that by 2045 there will be more than 174 million people with diabet.
At present, driven by multiple factors such as the continuous growth of diabetes patients in China, the successive entry of new diabetes treatment drugs into the medical insurance catalog, and the enhancement of patients' ability to pay, more and more domestic companies have begun to accelerate their deployment in this fie.
Sugar drugs have been approved for marketing one after anoth.
For example, on July 18, Sihuan Pharmaceutical announced that the new drug of the fourth-generation insulin analog degludec injection developed by Jilin Huisheng Bio-Pharmaceutical .
, L.
(referred to as Huisheng Bio), a non-wholly-owned subsidiary of the group, was launched on the mark.
The application has been accepted by the State Food and Drug Administrati.
At the same time, the announcement also pointed out that this product is the first domestically produced fourth-generation insulin analog insulin degludec that has applied for a new drug marketing application in China and has been accepted after the original research product Novo.
On July 7, Huahai Pharmaceutical issued an announcement stating that the Linagliptin tablets declared by the company have obtained the "Drug Registration Certificate", indicating that the variety can be officially marketed and sold in Chi.
Since it is approved for production in accordance with Category 4 chemicals, the Linagliptin tablets produced by Huahai Pharmaceutical are deemed to have passed the consistency evaluation of generic dru.
Linagliptin is a dipeptidyl peptidase-4 (DDP-4) inhibitor developed by Boehringer Ingelheim and launched in the United States in June 201 It is mainly used for the treatment of type 2 diabetes and to improve blood sugar contr.
In May 2018, the abbreviated new drug application for Linagliptin tablets submitted by Huahai Pharmaceutical to the US FDA was provisionally approved
Up to now, Huahai Pharmaceutical has invested about 82 million yuan in domestic research and development projects of linagliptin table.
Huahai Pharmaceutical said that the approval of linagliptin will further enrich the company's product line and enhance the company's market competitivene.
On July 5, Haisco Pharmaceuticals (Meishan) submitted a 4-type generic listing application for Gliclazide sustained-release tablets, which is expected to become the company's first approved oral hypoglycemic dr.
It is understood that Gliclazide is a second-generation sulfonylurea hypoglycemic dr.
The data shows that in 2021, in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, The sales of this variety are close to 6 billion yu.
It is worth mentioning that in recent years, Haisco has been accelerating its efforts in the diabetes drug mark.
Earlier, Haisco has won the first category of new drugs HSK7653 tablets and the 6 categories of generic drugs repaglinide metformin tablets (I), repaglini.
The clinical approval for Nemetformin Tablets (II), HSK7653 Tablets for Type 2 Diabetes has also entered Phase III clinical tria.
The industry believes that the huge market prospects of diabetes drugs will attract more and more pharmaceutical companies to enter the market, and at the same time, the increasing competition will force domestic companies to accelerate from generic drugs to Fast-follow and First-in-cla.
It is understood that in fact, a number of innovative drugs from domestic pharmaceutical companies have entered the clin.
For example, the ultra-long-acting antibody drug independently developed by Hongyun Huaning, which is administered once every two weeks and directly acts on the GLP-1 receptor, is already in clinical stage I.
Period; Huadong Medicine's subsidiary Doyle Bio's long-acting triple-target agonist DR10624 targeting GLP-1 receptor, GCG receptor and FGFR1c/Klothoβ has been approved for clinical use abro.
Disclaimer: In any case, Neither the information nor the opinions expressed in this article constitute investment advice to anyo.
According to the pathogenesis, diabetes can be divided into type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus and special type of diabetes mellit.
China is a big country with diabet.
According to relevant data, the number of diabetic patients in China will exceed 140 million in 202It is estimated that by 2045 there will be more than 174 million people with diabet.
At present, driven by multiple factors such as the continuous growth of diabetes patients in China, the successive entry of new diabetes treatment drugs into the medical insurance catalog, and the enhancement of patients' ability to pay, more and more domestic companies have begun to accelerate their deployment in this fie.
Sugar drugs have been approved for marketing one after anoth.
For example, on July 18, Sihuan Pharmaceutical announced that the new drug of the fourth-generation insulin analog degludec injection developed by Jilin Huisheng Bio-Pharmaceutical .
, L.
(referred to as Huisheng Bio), a non-wholly-owned subsidiary of the group, was launched on the mark.
The application has been accepted by the State Food and Drug Administrati.
At the same time, the announcement also pointed out that this product is the first domestically produced fourth-generation insulin analog insulin degludec that has applied for a new drug marketing application in China and has been accepted after the original research product Novo.
On July 7, Huahai Pharmaceutical issued an announcement stating that the Linagliptin tablets declared by the company have obtained the "Drug Registration Certificate", indicating that the variety can be officially marketed and sold in Chi.
Since it is approved for production in accordance with Category 4 chemicals, the Linagliptin tablets produced by Huahai Pharmaceutical are deemed to have passed the consistency evaluation of generic dru.
Linagliptin is a dipeptidyl peptidase-4 (DDP-4) inhibitor developed by Boehringer Ingelheim and launched in the United States in June 201 It is mainly used for the treatment of type 2 diabetes and to improve blood sugar contr.
In May 2018, the abbreviated new drug application for Linagliptin tablets submitted by Huahai Pharmaceutical to the US FDA was provisionally approved
Up to now, Huahai Pharmaceutical has invested about 82 million yuan in domestic research and development projects of linagliptin table.
Huahai Pharmaceutical said that the approval of linagliptin will further enrich the company's product line and enhance the company's market competitivene.
On July 5, Haisco Pharmaceuticals (Meishan) submitted a 4-type generic listing application for Gliclazide sustained-release tablets, which is expected to become the company's first approved oral hypoglycemic dr.
It is understood that Gliclazide is a second-generation sulfonylurea hypoglycemic dr.
The data shows that in 2021, in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, The sales of this variety are close to 6 billion yu.
It is worth mentioning that in recent years, Haisco has been accelerating its efforts in the diabetes drug mark.
Earlier, Haisco has won the first category of new drugs HSK7653 tablets and the 6 categories of generic drugs repaglinide metformin tablets (I), repaglini.
The clinical approval for Nemetformin Tablets (II), HSK7653 Tablets for Type 2 Diabetes has also entered Phase III clinical tria.
The industry believes that the huge market prospects of diabetes drugs will attract more and more pharmaceutical companies to enter the market, and at the same time, the increasing competition will force domestic companies to accelerate from generic drugs to Fast-follow and First-in-cla.
It is understood that in fact, a number of innovative drugs from domestic pharmaceutical companies have entered the clin.
For example, the ultra-long-acting antibody drug independently developed by Hongyun Huaning, which is administered once every two weeks and directly acts on the GLP-1 receptor, is already in clinical stage I.
Period; Huadong Medicine's subsidiary Doyle Bio's long-acting triple-target agonist DR10624 targeting GLP-1 receptor, GCG receptor and FGFR1c/Klothoβ has been approved for clinical use abro.
Disclaimer: In any case, Neither the information nor the opinions expressed in this article constitute investment advice to anyo.
